ClinicalTrials.gg
CompletedNCT02706678Updated Nov 8, 2024

Efficacy and Safety Study of the Switch From Cyclosporin to Tacrolimus in Renal Transplant Recipients

A Phase 4 interventional study of Tacrolimus sustained-release capsule in Renal Transplant Recipients, sponsored by Astellas Pharma China, Inc.. Completed at 9 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Astellas Pharma China, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 5 years 2 months after the study started (first participant enrolled Dec 2010, registered Mar 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The objective of this study is to evaluate the effects of tacrolimus sustained-release capsules replacing cyclosporin on kidney function of renal transplant recipients.

02

Conditions studied

  • Renal Transplant Recipients

Keywords

  • FK506
  • Renal transplant recipients
  • cyclosporin
03

In context

Lead sponsor

Astellas Pharma China, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 years of age, male or female
  • 1-5 years after kidney transplantation
  • The patient has been accepting cyclosporin-based therapy for ≥6 months, and the therapeutic regimen has kept stable for at least 4 weeks before inclusion
  • The dose of cyclosporin has kept stable for at least 4 weeks before inclusion
  • At least one of the cyclosporin-related adverse reactions is present or the answer to the 5th question in the questionnaire is "Yes" at the time of inclusion:
  • gingival hyperplasia and treatment requested by the patient
  • polytrichia and interventional therapy requested by the patient
  • post-transplantation hypertension
  • post-transplantation hyperlipemia (total cholesterol>5.7 mmol/L (220 mg/dl))
  • Serum creatinine\<200 μmol/l ( 2.3 mg/dl)
  • A promise is made to take measures during the study (women at childbearing ages).

Exclusion criteria

Exclusion Criteria:

  • Patients having accepted transplantation of other organs apart from kidney transplantation
  • Patients with 24-hour urine protein>2 g
  • Patients with /ALT, SGOT/AST or total continually increasing to more than twice the normal value(s)
  • Patients with infectious foci
  • Patients with serious diarrhea or vomiting, active upper gastrointestinal ulcers or malabsorption
  • Patients with serious heart or lung diseases or history of sugar tolerance abnormality or malignant tumors
  • Patients allergic to tacrolimus or other basic medications
  • Pregnant or lactating women
  • Patients having participated in other clinical trials within the previous month
  • Other patients who are considered by doctors unsuitable for the study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Tacrolimus sustained-release capsule group

    Oral

    Drug: Tacrolimus sustained-release capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in creatinine level

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change from baseline in creatinine level

    Time frame: Baseline and Weeks 1, 2, 4, 8 and 12

  2. Incidence of rejection reaction after drug use

    Time frame: Up to Week 24

  3. Plasma concentrations of tacrolimus

    Time frame: Weeks 1, 2, 4, 8, 12 and 24

  4. Change from baseline in blood pressure

    Diastolic pressure and systolic pressure

    Time frame: Baseline and Weeks 1, 2, 4, 8, 12 and 24

  5. Change from baseline in blood lipid

    Total cholesterol, high density lipoprotein, low density lipoprotein, triglyceride

    Time frame: Baseline and Weeks 1, 2, 4, 8, 12 and 24

  6. Change from baseline in liver function

    Aspartate aminotransferase, alanine aminotransferase, bilirubin

    Time frame: Baseline and Weeks 1, 2, 4, 8, 12 and 24

  7. Change from baseline in fasting blood glucose

    Time frame: Baseline and Weeks 1, 2, 4, 8, 12 and 24

  8. Change from baseline in gingival hyperplasia

    Time frame: Baseline and Week 24

  9. Change from baseline in polytrichia

    Time frame: Baseline and Week 24

  10. Safety assessed by Adverse Events

    Time frame: Up to 24 weeks

07

Study locations

9 sites
  • Beijing, China
  • Changchun, China
  • Chengdu, China
  • Guangzhou, China
  • Nanjing, China
  • Nanning, China
  • Shanghai, China
  • Shenyang, China
  • Wuhan, China
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2010 to primary completion in Aug 2012, 19 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 8, 2016
First posted
Mar 11, 2016
StartActual
Dec 29, 2010
Primary completionActual
Aug 1, 2012
CompletionActual
Aug 1, 2012
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02706678
Responsible party
Sponsor
First posted
Mar 11, 2016
Start date
Dec 29, 2010
Primary completion
Aug 1, 2012
Completion
Aug 1, 2012
Last update
Nov 8, 2024

Study contacts

Medical Director
study director · Astellas Pharma Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion